Stock Movers: Vertex, Centene, Oracle

Got story updates? Submit your updates here. ›

In this episode of Stock Movers, Bloomberg journalists analyze the performance of three major companies - Vertex, Centene, and Oracle. Vertex's drug to treat a kidney disorder met its goal in a late-stage trial, providing a boost to the biotech company's strategy of moving beyond cystic fibrosis treatments. Centene shares sank after the health insurer flagged rising medical costs and declining membership, with the company expecting a 35% or more decline in Affordable Care Act marketplace enrollment across the industry. Oracle posted quarterly cloud revenue that was better than expected and projected strong sales in the upcoming fiscal year, a sign the company is making good on its massive AI bookings.

Why it matters

These stock movements provide insights into the performance and strategies of major players in the biotech, healthcare, and technology industries, which are crucial sectors of the economy. The news highlights the challenges and opportunities facing these companies as they navigate changing market conditions and consumer trends.

The details

Vertex's drug to treat a kidney disorder met its goal in a late-stage trial, which could boost the company's strategy of moving beyond cystic fibrosis treatments. Centene's shares sank after the health insurer flagged rising medical costs and declining membership, with the company expecting a 35% or more decline in Affordable Care Act marketplace enrollment across the industry. Oracle posted quarterly cloud revenue that was better than expected and projected strong sales in the upcoming fiscal year, indicating the company is making progress in its AI-focused strategy.

• The Vertex drug trial results were announced on March 10, 2026.
• Centene reported its declining membership and cautious outlook on March 10, 2026.
• Oracle reported its quarterly results on March 10, 2026.